We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+26.11%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$191M
AUM Growth
+$49.9M
Cap. Flow
+$34.4M
Cap. Flow %
17.96%
Top 10 Hldgs %
57.43%
Holding
46
New
18
Increased
5
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$12.5M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$12M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.6M
4
ALIM
Alimera Sciences
ALIM
+$9.71M
5
OFIX icon
Orthofix Medical
OFIX
+$5.76M

Top Sells

Rank Stock Value
1
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$8.78M
2
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$8.6M
3
AERI
Aerie Pharmaceuticals
AERI
+$5.54M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$5.21M
5
CYNO
Cynosure, Inc. Class A
CYNO
+$4.53M

Sector Composition

Rank Sector Weight
1 Healthcare 66.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLXP
26
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$2.52M 1.32%
+31,250
New +$2.86M
MNKD icon
27
MannKind Corp
MNKD
$1.21B
$2.2M 1.15%
+109,380
New +$3.11M
MNKD icon
28
CALL
MannKind Corp
MNKD
$1.21B
$2.12M 1.11%
+105,400
New +$3M
LITS
29
Lite Strategy Inc
LITS
$32.8M
$1.75M 0.92%
7,883
– –
CCXI
30
DELISTED
ChemoCentryx, Inc.
CCXI
$1.66M 0.86%
249,700
-750,300
-75% -$5.21M
ACHV icon
31
CALL
Achieve Life Sciences
ACHV
$659M
$1.53M 0.8%
+59
New +$1.45M
KBIO
32
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$1.46M 0.76%
+67,112
New +$1.94M
VIRX
33
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.28M 0.67%
+922
New +$1.07M
EYPT icon
34
EyePoint Inc
EYPT
$1.03B
$1.16M 0.61%
28,331
-21,669
-43% -$953K
STRM
35
DELISTED
Streamline Health Solutions
STRM
$763K 0.4%
10,107
+4,509
+81% +$419K
MNTA
36
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$722K 0.38%
+62,000
New +$1.05M
RMTI icon
37
Rockwell Medical
RMTI
$28.4M
– –
-364
Closed -$418K
SVRA icon
38
Savara
SVRA
$1.12B
– –
-18,499
Closed -$599K
AERI
39
DELISTED
Aerie Pharmaceuticals
AERI
– –
-308,429
Closed -$5.54M
HZNP
40
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-500,000
Closed -$3.81M
CYNO
41
DELISTED
Cynosure, Inc. Class A
CYNO
– –
-170,000
Closed -$4.53M
HTWR
42
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-46,795
Closed -$4.39M
CBMX
43
DELISTED
CombiMatrix Corporation
CBMX
– –
-24,605
Closed -$849K
AVNR
44
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-567,000
Closed -$1.91M
CHTP
45
PUT
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
– –
-726,800
Closed -$3.22M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2014 Portfolio in Review

As of Q1 2014, Great Point Partners held 46 positions worth $191M, up 35% from $142M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Great Point Partners deployed $34.4M of net new capital in Q1 2014, opening 18 new positions and adding to 5 existing holdings. Its largest new stake was Tenax Therapeutics: 63 shares worth $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 44% a quarter earlier.

On the sell side, the largest reduction was FURIEX PHARMACEUTICALS INC COM STK (DE), an estimated $8.78M trimmed.

  • Great Point Partners's largest Q1 2014 buy was Tenax Therapeutics: 63 shares worth $11.1M.
  • Great Point Partners added most to VOLCANO CORPORATION COM STK in Q1 2014, an estimated $2.14M increase.
  • Great Point Partners's biggest Q1 2014 reduction was FURIEX PHARMACEUTICALS INC COM STK (DE), cutting an estimated $8.78M.
  • Great Point Partners fully exited Aerie Pharmaceuticals in Q1 2014, selling an estimated $5.54M.
  • Great Point Partners's ten largest holdings make up 57% of its $191M portfolio in Q1 2014.
  • Great Point Partners opened 18 new positions and closed 10 in Q1 2014.
  • Great Point Partners's portfolio value rose 35% quarter-over-quarter to $191M.

Based on Great Point Partners's 13F filing for Q1 2014, filed 15 May 2014.